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SUMMARY
Synovial sarcoma is an aggressive soft-tissue malignancy marked by a unique t(X;18) translocation
leading to expression of a chimeric SYT-SSX fusion protein. We report here a mouse model of syno-
vial sarcoma based on conditional expression of the human SYT-SSX2. Using this model, we have
identified myoblasts as a potential source of synovial sarcoma. Remarkably, within the skeletal
muscle lineage, while expression of the oncoprotein in immature myoblasts leads to induction of
synovial sarcoma with 100% penetrance, its expression in more differentiated cells induces
myopathy without tumor induction. We also show that early widespread expression of the fusion
protein disrupts normal embryogenesis, causing lethality.INTRODUCTION
Synovial sarcoma accounts for 7%–10% of all soft-tissue
sarcomas, frequently affecting adolescents and young
adults. Metastasis is common and usually targeted to
lungs, lymph nodes, and bone marrow (Weiss and Gold-
blum, 2001). The name ‘‘synovial sarcoma’’ was initially
coined for tumors arising near joints and having some mi-
croscopic resemblance to synovial tissue. However, this
tumor can arise, although rarely, in sites away from joints
such as head and neck, pharynx, lungs, and heart, which
contradicts this nomenclature. Several studies have dem-
onstrated a lack of synovial differentiation in synovial sar-
coma tumor cells and showed that these tumors express
markers of both epithelial and mesenchymal differentia-
tion, although they do not resemble any specific tissue
type (Fisher, 1986; Smith et al., 1995). Synovial sarcoma
is now regarded as a neoplasm of ‘‘uncertain differentia-tion.’’ Based on histopathology, synovial sarcomas are di-
vided into biphasic, monophasic, and poorly differentiated
subtypes. The presence of epithelioid cells often arranged
in whorls or primitive gland-like structures along with the
presence of spindle-shaped cells is a hallmark of the bi-
phasic subtype, while the monophasic subtype is marked
by a predominance of spindle cells. The poorly differenti-
ated subtype comprises primitive small round cells similar
to Ewing’s sarcoma. Immunohistochemistry plays an im-
portant role in diagnosis, the hallmark being expression
of both epithelial markers (cytokeratins) and mesenchy-
mal markers (vimentin). Bcl-2 overexpression is also fre-
quently observed in these tumors (Hibshoosh and Lattes,
1997; Pelmus et al., 2002).
Synovial sarcoma is marked by a signature genetic
event, the t(X;18) translocation-mediated fusion of the
SYT gene on chromosome 18q11 to either SSX1, SSX2,
or, very rarely, the SSX4 gene located on chromosomeSIGNIFICANCE
Synovial sarcoma is an aggressive, malignant soft-tissue tumor associated with significant mortality and morbid-
ity. The origin and pathogenesis of this disease are poorly understood, and response to current therapeutic
modalities is unsatisfactory. We report here a mouse model of synovial sarcoma that should significantly aid
our efforts to understand the pathogenesis of this disease and provide us with a reliable preclinical platform to
design and evaluate therapeutic strategies. The identification of a potential cell of origin for this disease and other
interesting observations with this model highlight its value and underscores the utility of the conditional genetic
approach in cancer modeling.Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 375
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Mouse Model of Synovial SarcomaXp11 (Clark et al., 1994; Crew et al., 1995; de Leeuw et al.,
1995; dos Santos et al., 2001; Limon et al., 1986; Panago-
poulos et al., 2001; Skytting et al., 1999; Smith et al.,
1987). This translocation is specific to synovial sarcoma.
While the presence of SYT-SSX transcript is considered
diagnostic for synovial sarcoma, the reciprocal SSX-SYT
transcripts are frequently absent within these tumors, im-
plicating SYT-SSX as the main suspect in the etiology
(Guillou et al., 2001; Hiraga et al., 1998; Ladanyi and
Bridge, 2000; Panagopoulos et al., 2001; Poteat et al.,
1995; Willeke et al., 1998). Further supporting this notion,
studies have demonstrated that human SYT-SSX1 trans-
forms rat fibroblasts, and the transformed cells formed tu-
mors within nude mice (Nagai et al., 2001). The 50 translo-
cation partner SYT is evolutionarily conserved, possesses
promoter architecture of housekeeping genes, and is
widely expressed in humans and mice (de Bruijn et al.,
1996, 2001). It is a putative transcriptional coactivator
and is thought to exert its effect by binding to chromatin
remodelers (Perani et al., 2003; Thaete et al., 1999). The
30 translocation partner SSX is a family of closely related
genes on the X chromosome and is believed to be tran-
scriptional corepressors. SSX expression in adults is re-
stricted to testes, although it is occasionally expressed
in certain tumors as well (Clark et al., 1994; Crew et al.,
1995; Gure et al., 1997; Lim et al., 1998). The t(X;18)-gen-
erated SYT-SSX fusion protein retains the activation do-
main of SYT along with the repressor domain of SSX, lacks
a DNA binding domain, and probably acts via interaction
with chromatin remodelers (dos Santos et al., 2000,
2001; Nagai et al., 2001). Several studies have also shown
that the type of translocation has a bearing on the progno-
sis and histology of synovial sarcoma. The SYT-SSX1 fu-
sion type has been shown to be associated with biphasic
histology and a worse prognosis compared to the pre-
dominantly monophasic SYT-SSX2 subtype (de Leeuw
et al., 1994; Kawai et al., 1998; Ladanyi et al., 2002; Ren-
wick et al., 1995). The underlying molecular basis of these
correlations is unknown.
Taking into consideration that synovial sarcoma is
a somatic genetic disease and tumorigenesis is depen-
dent upon a permissive microenvironment, we have de-
veloped a mouse that conditionally expresses human
SYT-SSX2 fusion protein in the presence of site-specific
Cre recombinase, thereby allowing us to investigate
the transforming role of this protein in chosen tissues at
specific times. The tissue or cell of origin for synovial
sarcoma is unknown. However, its frequent occurrence
within or in proximity to skeletal muscles raises the
possibility that transformation of an undifferentiated cell
of skeletal muscle lineage gives rise to these tumors.
This led us to investigate the skeletal muscle lineage as
a potential source of synovial sarcoma. In this study, we
report the generation of synovial-sarcoma-like tumors
with 100% penetrance in mice expressing SYT-SSX2
within skeletal-muscle-specific Myf5 lineage. These tu-
mors recapitulate the histopathological, immunohisto-
chemical, and transcriptional profile of human synovial
sarcoma.376 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.RESULTS
Generation of Targeted Mouse Lines
Human SYT-SSX2 cDNA generated from RNA isolated
from a synovial sarcoma tumor sample was used to con-
struct conditional SYT-SSX2 targeting vectors for target-
ing into the mouse ROSA26 locus on chromosome 6 fol-
lowing published procedures (Srinivas et al., 2001). The
ROSA promoter is ubiquitously active, thereby allowing
transcription of the fusion protein in any chosen tissue
following Cre-dependent recombination (Soriano, 1999;
Zambrowicz et al., 1997). Two variations of the targeting
vector were designed and used to generate two mouse
lines, SSM1 (synovial sarcoma mouse 1) and SSM2 (syno-
vial sarcoma mouse 2). SSM2 mice express SYT-SSX2-
IRES-EGFP bicistronic mRNA from the endogenous
ROSA promoter that enables monitoring of SYT-SSX2
expression by detecting EGFP-mediated fluorescence
(Figure 1A). The SSM1-targeting construct is similar
but lacks the IRES-EGFP marker gene. Between the
ROSA26 promoter and the SYT-SSX2 cDNA is a strong
transcriptional termination signal, NeoPA, flanked by
loxP sites (Figure 1A). In the absence of Cre, SYT-SSX2
is not transcribed. In the presence of Cre, Neo-pA is
excised and SYT-SSX2 transcription commences. By
controlling where and when Cre protein is produced, we
control where and when SYT-SSX2 fusion protein is
made. In the absence of Cre, both homozygous and het-
erozygous SSM1 and SSM2 mice (SSM denoting either
mouse lines) are normal, viable, and fertile with no expres-
sion of SYT-SSX2 or EGFP (data not shown).
To induce Cre expression within committed myoblasts
expressing the myogenic regulatory factor Myf5, we gen-
erated a Myf5-Cre driver such that Cre is expressed as
a second cistron from an IRES placed within the 30UTR
of the Myf5 gene as shown in Figure 1B (Jackson et al.,
1990; Jang and Wimmer, 1990). Homozygous and hetero-
zygous Myf5-Cre mice are viable and fertile. To confirm
the correct expression domain of Cre recombinase in
Myf5-Cre mice, we bred them to ROSA-YFP reporter
mice that express the yellow fluorescent protein (YFP)
within any Cre-expressing cell and its lineage (Srinivas
et al., 2001). Myf5 is a myogenic regulatory factor that
has an important role in the specification of skeletal mus-
cle lineage. Its expression begins early in embryogenesis
within immature myoblasts that eventually give rise to
adult skeletal muscle (Chanoine et al., 2004; Pownall
et al., 2002). Therefore, while early-stage Myf5-Cre/
ROSA-YFP embryos should have YFP expression within
dermomyotome component of somites, later-stage em-
bryos and adults should have YFP expression within skel-
etal muscle. This was consistently observed in our Myf5
lineage experiments (Figures 2Aa–2Ad).
SYT-SSX2 Expression within Myf5 Lineage
Induces Tumors
To express SYT-SSX2 within committed myoblasts
and their lineage, the conditional SSM (SSM1 or SSM2)
mice were bred to Myf5-Cre mice, and the resulting
Cancer Cell
Mouse Model of Synovial SarcomaFigure 1. Generation of Targeted Mouse Lines
(A) The SSM2-targeting vector comprises LoxP-flanked Neomycin resistance gene (Neo) with 30 polyadenylation signal (PolyA) and a 50 Pgk promoter.
This is followed by SYT-SSX2 cDNA and an encephalomyocarditis virus internal ribosomal entry site (IRES) fused to enhanced green fluorescent pro-
tein (EGFP) cDNA. This entire construct is flanked by a ROSA26 homology region. A negative selection cassette comprising a Pgk promoter driving
expression of diphtheria toxin A (DTA) was placed after the ROSA homology region. The SSM1 targeting vector has the same components except
IRES-EGFP. Presence of Cre leads to recombination between the two LoxP sites, thereby removing the Neomycin gene along with its polyA, allowing
transcription of SYT-SSX2 and EGFP from the endogenous ROSA promoter.
(B) The Myf5-targeting vector contains an encephalomyocarditis virus internal ribosomal entry site (IRES) fused to the Cre recombinase cDNA (Cre).
This is followed by neomycin resistance gene (Neo) expressed by MC1 promoter and flanked by two FRT sequences to allow removal of MC1-Neo by
breeding to a flippase-expressing mouse if desired. This entire construct is flanked by sequences homologous to region of the Myf5 30UTR. A thy-
midine kinase 1 (TK1)-negative-selection cassette was placed after the Myf5 homology region. This strategy enables transcription of a bicistronic
Myf5-IRES-Cre RNA leading to expression of Cre recombinase without interfering with Myf5 expression.Myf5-Cre/SSM progenies were followed. About 8% of
these mice were born significantly smaller than their sib-
lings and usually died by 2 months of age. However,
100% of the surviving Myf5-Cre/SSM mice (18/18) devel-
oped tumors between the ages of 3–5 months, demon-
strating complete penetrance in terms of tumor induction.
Control littermates (>100) that included mice harboring
only the SSM or Myf5-Cre alleles were followed for more
than a year with no tumor induction or any other abnormal-
ities. The Myf5-Cre/SSM mice that were born significantly
smaller and died before 2 months did not harbor any
apparent tumors and died of tumor-unrelated causes.
Multiple tumors (three to five per mouse) were detected
within Myf5-Cre/SSM mice upon necropsy. Detection of
very small tumors as well as potential metastasis was
aided by expression of the EGFP marker protein incorpo-
rated in our design of SSM2 mice. All tumors detected
within Myf5-Cre/SSM2 mice had intense green fluores-
cence, characteristic of EGFP expression (Figures 2Bc
and 2Be). Expression of SYT-SSX2 was also confirmed
by RTPCR on total RNA from tumors (see Figure S2B in
the Supplemental Data available with this article online).
Most tumors were located within skeletal muscle, a pre-
dicted outcome since the fusion protein was inducedwithin the skeletal-muscle-specific Myf5 lineage (Table
S1). However, a minority of small EGFP-positive tumors
were observed in nonskeletal muscle tissue, such as the
cerebellum (which is neither derived nor in close proximity
to Myf5-derived tissue) suggestive of potential metastasis
(Figure 2Bf).
Histological and Immunohistochemical
Profiles of Mouse Tumors Recapitulate
Human Synovial Sarcoma
On macroscopic examination, the mouse tumors were
vascularized, often having a chalky white appearance dis-
tinct from the surrounding tissue (Figure 2Bb, arrows).
Most frequently affected were the musculatures of the
limb near joints and the intercostal region (Figures 2Ba,
2Bb, and 2Bd and Table S1). The tumors are often hemor-
rhagic (Figure 3Ac, green arrow), with cystic spaces often
detected within larger tumors (Figure 3Ac, black arrow).
Histology revealed striking similarity to human synovial
sarcoma, with both biphasic (Figures 3Aa–3Ac) and
monophasic variants (Figure 3Ad) identified. However,
the monophasic variants greatly outnumbered biphasic
(13 monophasic and 3 biphasic). This correlates well with
data from human cases showing correlation of SYT-SSX2Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 377
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Mouse Model of Synovial SarcomaFigure 2. Tumor Induction within Myf5 Lineage
(A) E9.5 Myf5-Cre/ROSA-YFP embryos showing Myf5 lineage in somites based on whole-mount fluorescence (Aa). Ab shows a wild-type littermate
embryo. Adult Myf5-Cre/ROSA-YFP skeletal muscle sections demonstrate YFP expression ([Ac], red) within skeletal muscle fibers expressing skel-
etal-muscle-specific myosin ([Ad], green). Nuclei are marked blue by DAPI.
(B) Tumors within skeletal musculature of limbs (Ba and Bd) and intercostal region (Bb, arrows). Tumors are fluorescent due to EGFP expression ([Bc],
arrows, and [Be]). Figure Bf shows a fluorescent potential metastatic lesion in brain.with the monophasic subtype (Ladanyi et al., 2002). While
smaller tumors were usually monophasic, often containing
trapped skeletal muscle fibers (Figure 3Ad, black arrow),
the larger tumors usually showed biphasic histology with
epithelioid cells arranged in a glandular pattern amid
spindle cells (Figure 3Ab, black arrow). Myxoid changes
detected by alcian blue staining (Figure 3Ae) and fibrous
changes detected by Masson’s trichrome staining (Fig-
ure 3Af) also recapitulate features of human synovial
sarcoma.
As mentioned elsewhere, synovial sarcomas coexpress
epithelial as well as mesenchymal markers and often over-
express Bcl-2. This is faithfully recapitulated in tumors
generated in our mouse model that show expression of
epithelial cytokeratins (positive for cytokeratin AE1/AE2
cocktail and CAM5.2) as well as mesenchymal marker vi-
mentin (Figures 3Ba–3Bd). In humans, synovial sarcoma is
considered a high-grade tumor, which is recapitulated in
our model based on widespread expression of the prolif-
eration marker Mib (Figure 3Be). Since the tumors were
induced within skeletal muscle lineage, immunohisto-
chemistry for myogenin was done to rule out other muscle
tumors, such as rhabdomyosarcomas, that are usually
positive for myogenin (while synovial sarcomas are usually
myogenin negative). The tumors generated in our model
were negative for myogenin (Figure 3Bf). In summary,
based on histopathology and immunohistochemistry, the
mouse tumors strongly resemble humansynovial sarcoma.
Transcriptional Profiles of the Mouse Tumors
Recapitulate Human Synovial Sarcoma Profiles
To further compare the murine tumors to their human
counterparts, transcriptional profiling analysis using Affy-
metrix mouse genome 430 2.0 gene chip was performed378 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.on five independent tumors and compared to four skeletal
muscle samples from wild-type control mice. Hierarchical
clustering of preprocessed and normalized expression
profiles showed the expected segregation of tumors and
normal muscle samples (Figure 4A). Subsequent signifi-
cance analysis of microarrays (SAM) identified 1736 upre-
gulated and 2341 downregulated genes at a false discov-
ery rate (FDR) of <0.01 (Table S5). To determine if the
expression profile of these mouse tumors simulated hu-
man synovial sarcoma, we compared our gene expression
pattern to synovial sarcoma expression profiles present
within several published human tumor expression data
sets (Baird et al., 2005; Detwiller et al., 2005; Henderson
et al., 2005; Nielsen et al., 2002). We first rank-ordered
the genes in each data set according to their correlation
to synovial sarcoma and extracted a list of significantly
correlating genes as determined by permutation testing
at a p value of <0.01 (Golub et al., 1999). The murine tumor
data were similarly processed and converted to homolo-
gous human genes. The murine and human rank-ordered
lists were compared via Spearman correlation testing. The
results of the Spearman correlation showed small but sig-
nificant similarities between murine SYT-SSX2-induced
tumors and human synovial sarcomas (Table S2). This
supported our hypothesis that the murine tumors are in-
deed synovial sarcomas.
We reasoned that the small correlations observed in the
Spearman analysis were due to a previously unidentified
SYT-SSX gene expression signature and that we could
identify this signature by comparisons between the murine
and human tumor data sets. To test this hypothesis, we
employed a more sensitive statistical method, gene set
enrichment analysis (GSEA). GSEA offers a straightfor-
ward means of measuring the ‘‘enrichment’’ of one gene
Cancer Cell
Mouse Model of Synovial SarcomaFigure 3. Tumor Histology and Immunohistochemistry
(A) Biphasic histology (Aa and Ab) showing epithelioid components arranged in a glandular pattern ([Ab], arrow). Biphasic tumor showing a cystic
space ([Ac], black arrow) and hemorrhage ([Ac], green arrow). A monophasic tumor composed of spindle cells (Ad) showing trapped skeletal muscle
fibers ([Ad], arrow). Tumors show myxoid change detected by alcian blue (Ae) and fibrosis detected by Masson’s trichrome staining ([Af], black arrow).
(B) Tumors are positive for vimentin (Ba), CAM 5.2 (Bb), Cytokeratin AE1/AE2 (Bc), and Bcl-2 (Bd). Tumors express proliferation marker Mib (Be) and
are usually negative for myogenin (Bf).set against an ordered data set in which genes are ranked
according to their correlation to the phenotype of interest
(Supplemental Data). GSEA has been used previously to
compare data sets derived from different microarray plat-
forms and from different species (Sweet-Cordero et al.,
2005). We first derived an ‘‘SYT-SSX model gene set’’
from the murine tumor data and mapped the murine genes
to their human counterparts. An initial GSEA comparison
between this murine gene set and a human synovial sar-
coma data set (Detwiller et al., 2005) did not demonstrate
a statistically significant enrichment (ES 0.2, p = 0.48). This
lack of enrichment does not necessarily indicate a strong
dissimilarity between the murine model and the human
disease but instead could be due to the mode of selection
of the model signature or difficulties in comparing data
sets across species or platforms. We therefore used this
initial comparison as a ‘‘training set’’ to derive a common
signature between the murine model and the Detwiller
data set. We identified 55 genes that were enriched be-tween the murine tumors and the training data set and
named this list ‘‘SYT-SSX model synovial subset.’’ Impor-
tantly, this gene set was largely distinct from a set of 249
synovial-sarcoma-specific genes derived from the Detwil-
ler data set using SAM (only four genes overlapped be-
tween these two gene sets). To determine if this ‘‘SYT-
SSX model synovial subset’’ of genes truly represented
a new group of synovial sarcoma genes, we compared
the performance of this gene set with the performance
of a SAM-derived Detwiller synovial sarcoma gene set
(designated as ‘‘human tumor synovial cell sarcoma
gene set’’) using GSEA against three unique sarcoma
‘‘test data sets’’ (Baird, Nielsen, and Henderson data
sets). The entire process is schematically represented in
Figure 4B. The ‘‘SYT-SSX model synovial subset’’ is sig-
nificantly represented in only human synovial sarcomas
and not in other similar human sarcomas across all
human tumor data sets (Table 1). This demonstrates that
comparisons between the murine and human tumor dataCancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 379
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Mouse Model of Synovial SarcomaFigure 4. Microarray Analysis of Mouse Tumors
(A) Hierarchical clustering shows expected segregation of tumors and normal skeletal muscle.
(B) Strategy for gene set enrichment analyses. The initial GSEA is shown in (Ba). The SYT-SSX model synovial subset derived from this initial GSEA
is represented in (Bb). The human synovial sarcoma control gene set is represented by (Bc). All three gene sets were compared in sequence to the
phenotypes present in the remaining human tumor data sets (Bd).sets can reveal synovial sarcoma-specific genes that
could not otherwise be detected and further highlights
the similarity between our murine tumors and human
synovial sarcoma.
Myf5 Lineage Is a Potential Source
of Synovial Sarcoma
In human synovial sarcomas, expression of SYT-SSX
takes place from the endogenous SYT promoter, whereas
in our model it takes place from the ROSA promoter within
Myf5 lineage. We therefore looked for expression of SYT
within Myf5 lineage as supporting evidence that Myf5 lin-
eage could be a bona fide source of this tumor. We bred
the Myf5-Cre mice to ROSA-YFP reporter mice and
looked for coexpression of YFP and SYT in embryos as
well as in adult skeletal muscle of Myf5-Cre/ROSA-YFP
progenies. We found that SYT is widely expressed within
embryos that included almost all YFP-positive Myf5 line-
ages (Figure 5A, left panel). Interestingly, SYT expression
was also observed in a significant proportion of adult my-
onuclei (Figure 5A, right panel). To determine if SYT is ex-380 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.pressed in muscle satellite cells, we did double immunos-
taining for Pax7 and SYT that did not show any convincing
expression of SYT within Pax7-expressing satellite cells
(data not shown).
SYT-SSX2 Expression Restricts Myf5
Lineage Expansion
Synovial-sarcoma-like tumors within Myf5-Cre/SSM2
mice are intensely fluorescent due to expression of EGFP.
Surprisingly, however, the surrounding skeletal muscle
fibers are mostly GFP negative (Figure 5B). This observa-
tion could have a relatively trivial explanation, such as the
IRES driving EGFP expression being inefficient within
skeletal muscle as opposed to tumor cells. Alternatively,
the explanation could be more biologically profound: the
tumors are derived from Myf5-expressing cells, whereas
the majority of the skeletal muscle in Myf5-Cre/SSM2
mice, though of normal appearance, is not derived from
Myf5-expressing cells.
As part of an unrelated project, a conditional Hox gene
was placed in the ROSA locus followed by the same
Cancer Cell
Mouse Model of Synovial SarcomaTable 1. GSEA of Gene Sets Upregulated in SYT-SSX and Synovial Cell Sarcoma Tumors Compared to Human
Sarcoma Data Sets
SYT-SSX Model
Gene Set
SYT-SSX Model
Synovial Subset
Human Tumor Synovial Cell
Sarcoma Gene Set
Human Cancer
Phenotype Data Set ES NES
FWER
p Value ES NES
FWER
p Value ES NES
FWER
p Value
Baird et al.
Synovial cell sarcoma 0.167 0.780 0.791 0.582* 1.945* 0.001* 0.539* 2.030* 0.001*
Fibrosarcoma 0.230 1.084 0.379 0.352 1.184 0.364 0.206 0.749 0.713
Ewing’s sarcoma 0.160 0.731 0.739 0.213 0.706 0.790 0.314 1.151 0.368
Osteosarcoma 0.235 1.102 0.345 0.235 0.782 0.708 0.187 0.672 0.765
Rhabdomyosarcoma 0.182 0.854 0.739 0.254 0.848 0.627 0.209 0.756 0.799
Leiomyosarcoma 0.241 1.123 0.415 0.269 0.911 0.587 0.152 0.558 0.799
Liposarcoma 0.201 0.932 0.609 0.405 1.365 0.155 0.346 1.285 0.224
Malignant fibrous histiosarcoma 0.178 0.831 0.668 0.456 1.572 0.048 0.385 1.424 0.116
Henderson et al.
Monophasic synovial cell sarcoma 0.293 1.208 0.216 0.626* 1.565* 0.022* 0.712* 1.783* <0.001*
Alveolar rhabdomyosarcoma 0.272 1.106 0.372 0.493 1.236 0.224 0.526 1.301 0.168
Ewing’s sarcoma 0.276 1.127 0.342 0.476 1.185 0.266 0.327 0.818 0.702
Myxoid liposarcoma 0.243 0.989 0.470 0.418 1.060 0.439 0.280 0.699 0.764
Dedifferentiated chondrosarcoma 0.369 1.497 0.039 0.378 0.955 0.571 0.331 0.817 0.736
Embryonal rhabdomyosarcoma 0.236 0.974 0.524 0.358 0.927 0.584 0.603 1.501 0.042
Chondroblastoma 0.259 1.057 0.433 0.307 0.766 0.740 0.393 0.968 0.513
Fibromatosis 0.253 1.037 0.421 0.303 0.764 0.743 0.354 0.882 0.609
Well-differentiated liposarcoma 0.242 0.982 0.525 0.327 0.812 0.701 0.535 1.321 0.121
Lipoma 0.226 0.925 0.598 0.330 0.843 0.680 0.572 1.375 0.102
Osteosarcoma 0.325 1.316 0.142 0.364 0.903 0.623 0.353 0.874 0.651
Neurofibroma 0.206 0.837 0.697 0.444 1.113 0.349 0.495 1.226 0.230
Leiomyosarcoma 0.277 1.142 0.318 0.504 1.265 0.163 0.379 0.976 0.492
Chondrosarcoma 0.237 0.966 0.529 0.511 1.300 0.189 0.442 1.094 0.380
Chondromyxoid fibroma 0.270 1.093 0.379 0.543 1.392 0.098 0.448 1.104 0.360
Chordoma 0.330 1.344 0.132 0.566 1.372 0.107 0.551 1.369 0.111
Schwannoma 0.281 1.159 0.296 0.598 1.495 0.048 0.555 1.358 0.121
Nielsen et al.
Synovial cell sarcoma 0.293 0.942 0.566 0.828* 1.568* 0.044* 0.679* 1.842* 0.001*
Malignant fibrous histiosarcoma 0.400 1.267 0.295 0.462 0.868 0.669 0.511 1.423 0.125
Gastrointestinal stromal tumor 0.292 0.962 0.517 0.444 0.817 0.695 0.357 0.985 0.498
Schwannoma 0.435 1.307 0.215 0.437 0.816 0.635 0.394 1.026 0.454
Leiomyosarcoma 0.244 0.793 0.648 0.634 1.152 0.406 0.275 0.753 0.785
Liposarcoma 0.283 0.916 0.600 0.745 1.376 0.166 0.173 0.480 0.807
Enrichment of genes upregulated in the mouse model and in human synovial sarcoma was analyzed by GSEA in human sarcoma
data sets. The mouse model ‘‘synovial subset’’ comprises genes from the model set that show enrichment in an independent hu-
man sarcoma data set. Positive ES scores indicate enrichment in the cancer phenotype; negative ES scores indicate enrichment in
the comparator class (‘‘antienrichment’’). Asterisks indicate statistical significance. As expected, the human synovial sarcoma gene
set showed enrichment in human synovial sarcoma (positive ES score, significant FWER p value). Likewise, the mouse model
‘‘synovial subset’’ showed significant enrichment in human synovial sarcoma, while the full mouse model gene set showed nonsig-
nificant enrichment. Neither the full mouse model gene set nor the synovial subset were significantly enriched in other human can-
cers. ES, enrichment score; NES, normalized enrichment score; FWER, family-wise error rate.Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 381
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Mouse Model of Synovial SarcomaFigure 5. SYT Expression within Myf5 Lineage and Myf5 Lineage Restriction by SYT-SSX2
(A) SYT expression (red) is detected within YFP expressing Myf5 lineage (green) in Myf5-Cre/ROSA-YFP E15.5 embryos (left panel) and adult skeletal
muscle (right panel).
(B) A tumor arising near ribs (B, left panel and right panel) where all the tumor cells are expressing EGFP (red) while surrounding and trapped muscle
fibers expressing myosin (green) are negative for EGFP. Nuclei are stained blue by DAPI.
(C) Myf5 lineage in Myf5-Cre/ROSA-YFP E11.5 embryos (left panel) is marginally reduced in E11.5 Myf5-Cre/SSM2 embryo (middle panel) based on
whole-mount fluorescence. Insets show dermomyotomal regions at a higher magnification. Right panel shows wild-type littermate embryo.
(D) Myf5 lineage is robust within Myf5-Cre/ROSA-YFP E15.5 embryos (Da) but undetectable in E15.5 Myf5-Cre/SSM2 embryos (Db). Dc shows wild-
type littermate embryo. This is also apparent by comparing sections throughMyf5-Cre/ROSA-YFP E15.5 embryos (Dd) toMyf5-Cre/SSM2 E15.5 em-
bryos (De). In (Dd), lineage marker YFP (red) colocalizes with skeletal-muscle-specific MyoD (green) compared to near absence of the lineage marker
EGFP (green) in the presence of normal MyoD expression (red) in (De).
(E) Significant apoptosis (green nuclei) within somitic lineage of Myf5 expressing EGFP (red) in E11.5 Myf5-Cre/SSM2 embryos (left panel). This is in
contrast to absence of apoptosis (no green nuclei) within EGFP expressing Myf-5 lineage (red) near mesenchymal condensations of future ribs (right
panel, white arrow) of the same embryo.IRES-EGFP sequence used to construct the SSM2 mice.
This mouse was bred to the Myf5-Cre mouse, and the
skeletal muscle of the progeny showed readily detectable
IRES-driven EGFP expression (data not shown). There-
fore, lack of EGFP expression within skeletal muscle of
Myf5-Cre/SSM2 mice is not due to the IRES being ineffi-
cient in skeletal muscle, but rather is due to the absence
or reduction of the Myf5-derived cell lineage in these
mice. This implies that abrogating or severely restricting
the Myf5 lineage is compatible with normal development.
In our laboratory we have generated a very efficient condi-
tional cell ablation system in which an attenuated form of
the diphtheria toxin gene (DTA-176) is targeted to the
ROSA locus and dependent on Cre for its activation (Wu
et al., 2006). This mouse was bred to theMyf5-Cremouse,
thereby killing all Myf5-expressing cells in the progeny
containing both alleles. Remarkably, these pups are born
with apparently normal musculature (Figure S2A).
Comparative analysis of Myf5-Cre/SSM2 with Myf5-
Cre/ROSA-YFP embryos was carried out to analyze Myf5
lineage restriction by SYT-SSX2. This revealed that EGFP-
mediated fluorescence within Myf5-Cre/SSM2 embryos
at E11.5 (Figure 5C, middle panel) was comparable to
stage-matchedMyf5-Cre/ROSA-YFP embryos (Figure 5C,382 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.left panel). However, Myf5 lineage in Myf5-Cre/SSM2 em-
bryos is almost absent by E15.5 (Figure 5Db) when com-
pared to stage-matched Myf5-Cre/ROSA-YFP embryos
(Figure 5Da). This suggested that SYT-SSX2 expressing
Myf5 lineage is not viable. We next performed TUNEL
assay on serial sections of Myf5-Cre/SSM2 embryos at
E11.5 (when Myf5 lineage is still detectable) and found
apoptosis withinMyf5 lineage (Figure 5E, left panel). An in-
triguing observation was that Myf5 lineage near condens-
ing mesenchyme of future rib cartilages does not show
apoptosis (Figure 5E, right panel). This suggests that the
microenvironment near cartilages may have survival fac-
tors preventing apoptosis by SYT-SSX2 that could partly
explain the predilection of this tumor to arise near joints
containing articular cartilages. Although the Myf5 lineage
is restricted by SYT-SSX2 expression, MyoD expression
(marker for early skeletal muscle lineage) was normal
within Myf5-Cre/SSM2 E15.5 embryos, demonstrating
that apoptosis within Myf5 lineage does not compromise
skeletal muscle genesis (Figures 5Dd and 5De).
Taken together, the above results suggest that SYT-
SSX2 induces apoptosis within Myf5 lineage and, only
because Myf5-expressing cells are largely dispensable
with respect to the formation of skeletal muscle, that
Cancer Cell
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(A) Disorganized Hprt-Cre/SSM2 fetal tissue (right panel) expressing EGFP (left panel).
(B) Pax3 lineage within E10.5 Pax3-Cre-KI/SSM2 embryo is detectable (left panel). Right panel shows wild-type (WT) littermate embryo.
(C) The left panel shows Pax7 lineage within Pax7-Cre/ROSA-YFP E15.5 embryos, while the middle panel shows significantly reduced Pax7 lineage
within Pax7-Cre/SSM2 embryo based on whole-mount fluorescence. The maxillary and nasal regions of Pax7-Cre/SSM2 embryo show a larger pro-
portion of surviving Pax7 lineage compared to other regions (white arrows). Right panel shows wild-type (WT) littermate embryos.
(D) Myopathic skeletal muscle of Myf6-Cre/SSM adult mice show abnormal wavy fibers, myonuclear chain ([Dc], arrow), and significant variations in
cross-sectional diameter between fibers ([Dd]) with occasional vacuolation ([Dd], black arrow) and central nuclei ([Dd], blue arrow). (Da) and (Db) show
skeletal muscle sections from wild-type (WT) littermate. The myopathic skeletal muscle expresses EGFP detected in whole mount (De) and sections
(Df). Apoptosis within myopathic muscles is detected by TUNEL assay ([Dh], green nuclei). (Dg) shows a TUNEL-negative control skeletal muscle
section from wild-type (WT) littermate. (Di) and (Dj) correspond to the same field in (Dg) and (Dh) and show nuclei stained blue by DAPI.Myf5-Cre/SSM mice have the opportunity to develop tu-
mors at later times. Synovial sarcoma induction in our
mouse model appears to be postnatal with a short latency
period.
Early Embryonic Expression of SYT-SSX2
Induces Lethality
We next investigated whether SYT-SSX2 expression
within any lineage, if induced early, could also generate
synovial sarcoma. To investigate this, we bred our condi-
tional SSM mice to Hprt-Cre mice that express Cre in very
early-cleavage-stage embryos (Tang et al., 2002). No
Hprt-Cre/SSM pups were ever recovered, indicating em-
bryonic lethality. Although attempts to recover Hprt-Cre/
SSM embryos failed, highly disorganized EGFP-express-
ing fetal tissue was detected at E8.5, indicating a dominant
disruptive effect of SYT-SSX2 on normal embryonic devel-
opment (Figure 6A).
We next investigated if SYT-SSX2 expression within
skeletal muscle progenitors genetically upstream of Myf5,
such as those expressing Pax3 and Pax7, leads to synovial
sarcoma induction. We started by breeding the conditionalSSM mice to Pax3-Cre knockin mice that express Cre
recombinase from the endogenous Pax3 locus (Engleka
et al., 2005).Pax3 is a transcription factor playing an impor-
tant role in premigratory neural crest cells, as well as in early
precursors of skeletal muscle (Epstein, 2000). No Pax3-
Cre/SSMpupswere obtained.However, embryos express-
ing EGFP in Pax3 lineage pattern were recovered at E10.5
(Figure 6B) but not at E13.5, indicating that embryonic
lethality occurred within this developmental time frame.
Next, the SSM mice were bred to mice expressing Cre
from Pax7 locus via an IRES placed in the 30UTR of Pax7
(Keller et al., 2004b). Pax7 is a transcriptional factor that
has important functions in skeletal muscle progenitors,
particularly in the formation of muscle stem cells (satellite
cells) that contribute to postnatal skeletal muscle forma-
tion and skeletal muscle regeneration (Jostes et al.,
1990; Oustanina et al., 2004). Although no live progenies
were obtained, Pax7-Cre/SSM2 embryos were recovered
at E15.5, indicating either late-embryonic or perinatal
lethality (Figure 6C, middle panel).
Comparison of Pax7-Cre/ROSA-YFP (Figure 6C, left
panel) and Pax7-Cre/SSM2 (Figure 6C, middle panel)Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 383
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eage within Pax7-Cre/SSM2 based on EGFP fluores-
cence. However, compared to other regions, a greater
proportion of Pax7 lineage was detected in the maxillary
and nasal regions of Pax7-Cre/SSM2 embryos
(Figure 6C, arrows). This suggests that SYT-SSX2-ex-
pressing Pax7 lineage is mostly not viable, except in prox-
imity to the cartilaginous regions of developing maxilla and
nasal turbinates. These observations are in good agree-
ment with those made within Myf5-Cre/SSM2 embryos.
Expression of SYT-SSX2 within Differentiated Cells
of Skeletal Muscle Lineage Leads to Myopathy
We next investigated the effect of inducing SYT-SSX2
expression within more differentiated cells of skeletal
muscle lineage. Myf6 (Mrf4) is a myogenic regulatory fac-
tor expressed within myocytes and myofibers, a popula-
tion more differentiated than and genetically downstream
of Myf5-expressing myoblasts (Chanoine et al., 2004;
Pownall et al., 2002). We have previously described the
generation of mice expressing Cre from the Myf6 locus
via IRES (Keller et al., 2004a). These Myf6-Cre mice
were bred to SSM mice. Although none of the resulting
Myf6-Cre/SSM progenies developed tumors, all of them
(8/8) developed myopathy and eventually died by 6
months of age. This was an unexpected observation since
no human myopathy has been reported to be associated
with SYT-SSX.
The myopathy within Myf6-Cre/SSM mice is character-
ized by abnormal wavy fibers and limited rhabdomyolysis
(Figure 6Dc). Intrafiber vacuolation (Figure 6Dd, black
arrow) and central nuclei (Figure 6Dd, blue arrow) further
indicate skeletal muscle damage. Skeletal muscle regen-
eration was indicated by the presence of myonuclear
chains (Figure 6Dc, arrow). These abnormal skeletal mus-
cle fibers expressed EGFP, indicating expression of
SYT-SSX2 (Figures 6De and 6Df). Significant apoptosis
within these myopathic fibers was detected by TUNEL
assay (Figure 6Dh), suggesting that SYT-SSX2 induces
apoptosis within differentiated skeletal muscle fibers that
leads to myopathy.
DISCUSSION
We report herein a mouse model of synovial sarcoma. This
model recapitulates human synovial sarcoma based on
clinical presentation, histology, immunohistochemical
features, genetic signature (presence of SYT-SSX), and
transcriptional profile. A targeted conditional strategy was
adopted, enabling expression of the unique signature pro-
tein of synovial sarcoma, the SYT-SSX2 fusion protein, in
chosen target cells. Tissue microenvironment is extremely
important in tumorigenesis. Oncoproteins expressed in
inappropriate microenvironments may not induce tumors
or lead to biological effects unrelated to tumor formation.
A conditional strategy circumvents such problems. A sur-
prising outcome of our study is the identification of skele-
tal muscle lineage as a source of this tumor. Tumors were
generated within Myf5-Cre/SSM mice with 100% pene-384 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.trance, indicating that the fusion protein itself is sufficient
to induce the chain of events leading to synovial sarcoma.
In this context, it will be interesting to know whether con-
tinuous presence of SYT-SSX2 is required for tumor pro-
gression. We are currently investigating this possibility. It
is also noteworthy that no tumors were detected by gross
examination at necropsy within Myf5-Cre/SSM mice till
after weaning (3 weeks of age) indicating that, at least
in our model, the transformation may occur after birth,
with a relatively short latency period.
Tumors were generated within Myf5 lineage, but not
within the more differentiated Myf6 lineage, thereby nar-
rowing down the suspected cell of origin to myoblasts
(Figure 7). Since we suspect tumor origin in our model to
be postnatal, the best cellular candidate is Myf5-express-
ing myoblasts arising from activated satellite cells (muscle
stem cells). However, quiescent satellite cells themselves,
postnatally, could also be a potential source of synovial
sarcoma. Satellite cells are marked by expression of
Pax7. Expression of SYT-SSX2 within Pax7 lineage in-
duced embryonic lethality. However, this does not pre-
clude Pax7-expressing cells from being a potential source
of synovial sarcoma. In humans, the translocation is spo-
radic, and if it does occur within the Pax7 compartment
only some of these cells may harbor the translocation.
However, by breeding Pax7-Cre mice with SSM mice,
we expressed the fusion protein in virtually all Pax7-ex-
pressing cells and their lineage, thereby potentially over-
loading the system, causing lethality. Moreover, Pax7-ex-
pressing cells are not unique to the skeletal muscle
lineage, as it also plays important roles in patterning of
the dorsal neural tube during embryogenesis. However,
after birth, Pax7 expression is restricted to skeletal muscle
satellite cells. To determine the possible role of the Pax7
lineage as a source of synovial sarcoma in the context of
skeletal muscle lineage, we are currently adopting the
use of a CreER fusion protein instead of straight Cre re-
combinase. Pax7-IRESCreER allows modulation of the
dosage and timing of Cre activation, by the requirement
of the addition of the exogenous, small-molecule-inducing
factor tamoxifen (Hayashi and McMahon, 2002). The pres-
ence of the SYT-SSX2 fusion protein in Pax7-expressing
satellite cells could activate these quiescent cells and
direct them toward a tumorigenic phenotype.
In human synovial sarcoma, SYT-SSX1 is associated
with biphasic histology, while SYT-SSX2 is associated
with monophasic subtype (Ladanyi et al., 2002). This is
recapitulated in our model, where we see a much higher
frequency of monophasic tumors (13 monophasic versus
3 biphasic). An intriguing observation was a correlation
between tumor size and tumor histology. While the smaller
tumors showed monophasic histology, the larger tumors
were biphasic. This seems to indicate that histology of
the tumor may be a function of its ‘‘maturation’’ with
more mature and advanced (hence larger) tumors associ-
ated with biphasic histology. The SYT-SSX1 type of fusion
might be responsible for a faster rate of tumor ‘‘matura-
tion’’ compared to SYT-SSX2 such that ‘‘maturation’’ is
a reflection of mesenchymal-to-epithelial transition within
Cancer Cell
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ments
Summary of results of expressing SYT-SSX2
fusion protein within various cells of skeletal
muscle lineage. The yellow box highlights the
suspected cell of origin: myoblasts arising
from postnatal satellite cells.the tumor, accounting for the statistical correlation of
SYT-SSX1 to the biphasic subtype.
Synovial sarcoma in humans frequently arises near
joints of limbs, a fact that is recapitulated in our model
(Table S1). In Myf5-Cre/SSM embryos, we observed a
greater proportion of surviving Myf5 lineage near future
rib cartilages, which were also the most frequent site of
tumor induction in our model. This suggests a possible
hypothesis that cartilaginous components may provide
a particularly favorable niche for the survival of SYT-
SSX2-expressing cells, thereby allowing their continued
progression toward neoplasia, a potential explanation for
occurrence of synovial sarcomas near joints that have
cartilaginous articular regions.
Expression profiling of the synovial-sarcoma-like tu-
mors in our mouse model revealed correlations between
the murine model and human synovial sarcomas, estab-
lishing our model as a bona fide synovial sarcoma model.
There are challenges in performing such comparisons,
however. For example, while the human data sets com-
pared synovial sarcomas to other tumors, our ‘‘SYT-SSX
model’’ gene signature was obtained by comparing the
murine tumors to normal mouse skeletal muscle because
we lacked appropriate analogous murine tumors for such
a comparison. Thus, our murine ‘‘SYT-SSX model gene
set’’ likely represents both SYT-SSX dysregulated genes
and genes that are dysregulated as a result of the transfor-
mation process. These ‘‘transformation’’ genes are likely
to be dysregulated across many different sarcomas. This
complicates comparisons between the human and murine
tumors. We were able to extract a unique synovial sar-
coma signature by comparing murine and human datasets. We then validated this signature by independently
comparing it to human data sets not used in the initial
screening process. This signature performed comparably
to the human synovial signature in subsequent validation
GSEAs and showed significant correlation between our
synovial model and the human tumor profiles. This sup-
ports the notion that comparison of model systems to hu-
man tumors provides a unique opportunity to identify tu-
mor-specific genes that could not be identified through
comparative analysis of human tumors.
Disruption of normal embryogenesis by early ubiqui-
tous expression of SYT-SSX2 underscores the dominant,
disruptive effect of this protein on normal development,
a potential explanation for the rarity of this tumor. The
translocation itself might not be as rare an event as the
disease itself. However, due to its strong disruptive effect,
most embryos harboring this translocation early in devel-
opment would be spontaneously aborted. This disruptive
effect was also apparent within the more differentiated
cells of skeletal muscle lineage, where myopathy was
induced within musculature of Myf6-Cre/SSM mice. The
myopathy was observed in the absence of tumor induc-
tion. However, it is possible that purposeful introduction
of ‘‘second genetic hits’’ such as inactivation of Trp53 or
Ink4a/ARF in association with SYT-SSX2 might lead to
the induction of synovial sarcoma in differentiated mus-
cle. These ‘‘second genetic hits’’ may be required to initi-
ate dedifferentiation of mature muscle, thereby facilitating
tumor induction by SYT-SSX2, a possibility currently
being tested.
Our laboratory has previously modeled alveolar rhabdo-
myosarcoma (ARMS) in mouse (Keller et al., 2004a). It isCancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc. 385
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sarcoma model. Both tumors appear to be induced
by chromosomal translocations generating unique but
separate fusion genes: Pax3-Fkhr or Pax7-Fkhr for
ARMS and SYT-SSX1 or SYT-SSX2 for synovial sarcoma.
Both mouse models made use of a Cre/loxP-based condi-
tional approach for expressing the respective fusion
genes, although the specific strategies differed. The differ-
ence in strategy was dictated by differences in the ex-
pression patterns of the fusion gene. In ARMS, the
expression pattern of PAX3-FKHR is controlled by the
cis-regulatory elements associated with the Pax3 locus,
which has a specific expression domain in developing
mouse embryo. To preserve this specific expression
pattern, we chose to generate the fusion gene in response
to Cre at the normal Pax3 locus by juxtaposing the ap-
propriate Fkhr genomic sequences to that locus (Keller
et al., 2004a). In the absence of Cre, the Pax3 locus re-
tained normal Pax3 function, while Cre-mediated recom-
bination replaces Pax3 with the Pax3-Fkhr fusion gene.
In synovial sarcoma, the expression pattern of the SYT-
SSX fusion gene is controlled by the cis-regulatory ele-
ments associated with the SYT locus, which has a wide-
spread expression in developing mouse embryo. In this
case, we could target the human SYT-SSX2 fusion
cDNA to the ubiquitously expressed ROSA26 locus and
use Cre to activate its expression in chosen tissues or
cell types. Activation of either fusion protein, Pax3-Fkhr
or SYT-SSX2, during early embryogenesis leads to
embryonic lethality. However, while early expression of
SYT-SSX2 in response to Hprt-Cre leads to very early
lethality due to extensive disorganization of embryonic
tissue, the midgestation lethality associated with expres-
sion of the Pax3-Fkhr fusion gene, on the other hand, is
a partial phenocopy of Pax3 deficiency, a consequence
of this fusion protein turning off the normal Pax3 locus
(Keller et al., 2004b). The more extensive perturbations
of development induced by SYT-SSX2 may reflect its
more ubiquitous expression pattern and broader pertur-
bations of transcription.
In the ARMS model, expressing Pax3-Fkhr within differ-
entiating skeletal muscle lineage of Myf6 induced tumors,
albeit at very low penetrance (1/200 mice). Cointroduc-
tion of conditional mutations in either Trp53 or INK4a/
ARF increased the penetrance to nearly 100%. In con-
trast, SYT-SSX2 expression within Myf6 lineage induced
myopathy without tumor induction, while expression
withinMyf5 lineage induced synovial-sarcoma-like tumors
with 100% penetrance. Therefore, either SYT-SSX2 has
a stronger effect than Pax3-Fkhr in terms of respective
tumor induction or in the synovial sarcoma model we tar-
geted a population of cells that are more vulnerable to
transformation by SYT-SSX2.
In summary, we report here the generation of a mouse
model of synovial sarcoma based on a conditional, ge-
netic strategy and demonstrate that Myf5-expressing
myoblasts are a potential source of this tumor. This model
should significantly aid our efforts in understanding the
pathogenesis of this disease and serve as a useful386 Cancer Cell 11, 375–388, April 2007 ª2007 Elsevier Inc.preclinical platform to design and evaluate therapeutic
modalities.
EXPERIMENTAL PROCEDURES
Targeted Mouse Line Production and Genotyping
Human SYT-SSX2 cDNA was obtained by RTPCR on total RNA from
a synovial sarcoma tumor that was obtained as a deidentified patient
sample through an approved University of Utah Institutional Review
Board Protocol. This was used to generate targeting vectors as out-
lined in the Supplemental Data.
A clone consisting of an 8.4 kb segment of the Myf5 region including
the 30UTR was isolated from a l bacteriophage library of mouse strain
SvJ-129 (Stratagene). This was used to generate the Myf5-Cre-target-
ing vector as outlined in the Supplemental Data.
Genotyping was carried out using PCR protocols and Southern
blotting outlined in Figure S1 and the Supplemental Data. All studies
involving animal subjects were approved by the University of Utah
Institutional Animal Care and Use Committee and conducted strictly
in accordance with the relevant protocol.
Histology and Immunohistochemistry
For histology, specimens were fixed overnight in 4% paraformalde-
hyde and embedded in paraffin wax following standard procedure.
Four to eight micrometer sections were cut and mounted on slides
for standard hematoxylin and eosin (H&E) staining, Masson’s tri-
chrome staining, or alcian blue staining.
Immunohistochemistry on 4 mm sections of paraffin-embedded
samples was carried out by the ARUP laboratories at the University
of Utah. Counterstaining was done with hematoxylin. For fluores-
cence-based detection, immunohistochemistry was performed on
8–12 mm frozen sections on samples fixed in 4% paraformaldehyde
at 4C for 3 hr. Please refer to the Supplemental Data for the list of
primary and secondary antibodies used.
TUNEL Assay
TUNEL assay was performed using a fluorescein In Situ Cell Death De-
tection Kit (Roche) according to the manufacturer’s instructions.
Microarray Analysis
RNA was extracted from tumors of female Myf5-Cre/SSM mice as well
as from the skeletal muscle of wild-type age-matched female mice us-
ing TRIzol (Invitrogen) and purified using an RNeasy kit (Qiagen). A
complete description of microarray analysis is provided in the Supple-
mental Data. The microarray data have been deposited in NCBI’s Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and
are accessible through GEO Series accession number GSE6461.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, three supplemental figures, and seven supplemental tables
and can be found with this article online at http://www.cancercell.
org/cgi/content/full/11/4/375/DC1/.
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